Anti-Mouse Monoclonal Antibody to Human CD38 (Clone: 38.F2)

CD38 glycoprotein is a particularly attractive target on malignant plasma cells at all stages of disease and in Chronic lymphocytic leukemia (also called CLL) patients with a poor clinical prognosis. It is highly expressed in lymphoid tumors including multiple myeloma, AIDS-associated lymphomas, and post-transplant lymphoproliferation. In contrast, the molecule is detectable only at very low levels in mature lymphocytes or in nonhematopoietic tissues. Therputic Anti-CD38 antibodies (e.g. Daratumumab) can induce strong antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity to kill tumors. Anti-Human CD38 Antibody (38.F2), mAb, Mouse is produced from a hybridoma resulting from the fusion of SP2/0 myeloma and B-lymphocytes obtained from a mouse immunized with recombinant human CD38. Protein function: Synthesizes the second messagers cyclic ADP-ribose and nicotinate-adenine dinucleotide phosphate, the former a second messenger for glucose-induced insulin secretion. Also has cADPr hydrolase activity. Also moonlights as a receptor in cells of the immune system. [The UniProt Consortium]